On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company’s COVID-19 vaccine candidate. Crossover ensures the administration of active vaccine to all participants in the trials and was begun for Novavax’ Phase 2b trial in South Africa and its pivotal Phase 3 trial in the UK.

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.